Cellectar Biosciences, Inc. (CLRB) announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome ("BNS") with iopofosine I 131 and the second is the review of the company’s CLOVER WaM pivotal study of iopofosine I 131.The company will present these data at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) on Oct. 17, 2024, in Prague, Czech Republic.About Cellectar Biosciences’ Iopofosine I 131Iopofosine I 131 is a potential first-in-class, novel ...